Literature DB >> 6521493

Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens.

D J McKenna, G H Towers, F S Abbott.   

Abstract

Alkaloid constituents in Myristicaceous bark and leaf samples and in purportedly hallucinogenic preparations derived from Myristicaceous sources were qualitatively and quantitatively analyzed using TLC, GC, alkaloid precipitation tests and GC/MS. Fourteen of the 27 bark and leaf samples analyzed contained detectable amounts of alkaloids. The major bases were N,N-dimethyltryptamine (DMT) and/or 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); much smaller amounts of tryptamine and/or N-methyl-tryptamine (NMT) were also usually present. beta-Carbolines were not detected in the bark or leaf samples. Considerable variation in alkaloid profiles was found, extending to different collections of the same species. Fourteen of the 20 Virola samples contained alkaloids; none of the 6 Iryanthera species had detectable alkaloids. Osteophloem platyspermum contained an indolic base, identified as N-methyl-tryptophan methyl ester. Seven samples of an orally-ingested drug made from Virola spp. were analyzed. All except one contained substantial amounts of tryptamines; the types and proportions of tryptamines present varied greatly between samples. Samples of Yanomama snuff including various admixtures were analyzed and all components but one contained tryptamines. The drug samples having the highest concentrations of alkaloids contained 15-20 mg/g dry wt while the Myristicaceous bark and leaf samples had much lower concentrations ranging from 0.04 to 0.25 mg/g dry wt. beta-Carbolines were detected as trace constituents in only two of the Myristicaceous drug samples. Four Myristicaceous paste samples were bioassayed in self-experiments. Two of the samples were devoid of detectable hallucinogenic or physiological activity, while some degree of oral activity was detected in two other samples. The activity of a number of tryptamine derivatives as monoamine oxidase inhibitors (MAOI) was investigated using an in vitro enzyme assay. Activity was measured using single compounds and mixtures of compounds and the results were compared to the activity of samples of orally-ingested Myristicaceous pastes. Tryptamine derivatives had significantly less MAOI activity than the activity of beta-carboline derivatives measured in a previous study. Some structural correlations for MAOI activity were found for the tryptamine derivatives. Samples of orally-ingested Myristicaceous pastes were assayed for MAOI activity. The inhibition elicited by the paste samples was closely matched by mixtures of tryptamine standards having comparable proportions and concentrations.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6521493     DOI: 10.1016/0378-8741(84)90048-5

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  11 in total

1.  The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.

Authors:  Kirsten Krebs-Thomson; Erbert M Ruiz; Virginia Masten; Mahalah Buell; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-30       Impact factor: 4.530

Review 2.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

3.  Ethnopharmacological table on some reputedly psychoactive fumigatories among Middle and South American natives.

Authors:  P A De Smet
Journal:  Pharm Weekbl Sci       Date:  1985-10-25

4.  Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience.

Authors:  David Wyndham Lawrence; Robin Carhart-Harris; Roland Griffiths; Christopher Timmermann
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

Review 5.  Natural Products Inhibitors of Monoamine Oxidases-Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma.

Authors:  Narayan D Chaurasiya; Francisco Leon; Ilias Muhammad; Babu L Tekwani
Journal:  Molecules       Date:  2022-07-04       Impact factor: 4.927

6.  Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects.

Authors:  Rafael L Lancelotta; Alan K Davis
Journal:  J Psychoactive Drugs       Date:  2020-03-09

7.  A β-carboline derivative-based nickel(ii) complex as a potential antitumor agent: synthesis, characterization, and cytotoxicity.

Authors:  Jing-Mei Yang; Yan-Hong Zhu; Sheng Chen; Xing Lu; Yi-Ming Wu; Feng-E Ma; Liang-Ping Li; Yang Yang; Zhen-Hao Shi; Kun-Yuan Huang; Xue Hong; Ping Jiang; Yan Peng
Journal:  Medchemcomm       Date:  2017-11-24       Impact factor: 3.597

8.  Acute Biphasic Effects of Ayahuasca.

Authors:  Eduardo Ekman Schenberg; João Felipe Morel Alexandre; Renato Filev; Andre Mascioli Cravo; João Ricardo Sato; Suresh D Muthukumaraswamy; Maurício Yonamine; Marian Waguespack; Izabela Lomnicka; Steven A Barker; Dartiu Xavier da Silveira
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

9.  Synthesis and Characterization of 5-MeO-DMT Succinate for Clinical Use.

Authors:  Alexander M Sherwood; Romain Claveau; Rafael Lancelotta; Kristi W Kaylo; Kelsey Lenoch
Journal:  ACS Omega       Date:  2020-12-02

10.  Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.

Authors:  Fernanda Palhano-Fontes; Dayanna Barreto; Heloisa Onias; Katia C Andrade; Morgana M Novaes; Jessica A Pessoa; Sergio A Mota-Rolim; Flávia L Osório; Rafael Sanches; Rafael G Dos Santos; Luís Fernando Tófoli; Gabriela de Oliveira Silveira; Mauricio Yonamine; Jordi Riba; Francisco R Santos; Antonio A Silva-Junior; João C Alchieri; Nicole L Galvão-Coelho; Bruno Lobão-Soares; Jaime E C Hallak; Emerson Arcoverde; João P Maia-de-Oliveira; Dráulio B Araújo
Journal:  Psychol Med       Date:  2018-06-15       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.